An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.
Arman BY. et al, (2023), Int J Mol Sci, 25
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Boby ML. et al, (2023), Science, 382
Accelerating antiviral drug discovery: lessons from COVID-19.
von Delft A. et al, (2023), Nat Rev Drug Discov, 22, 585 - 603
Turning high-throughput structural biology into predictive inhibitor design.
Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.
Mould AW. et al, (2022), CNS Drugs, 36, 1 - 16
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Yang H. et al, (2021), Cell Rep, 35
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Boby ML. et al, (2020)
Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.
Donnison T. et al, (2020), Vaccine, 38, 5036 - 5048
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Esposito I. et al, (2020), Sci Transl Med, 12
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
von Delft A. et al, (2018), Vaccine, 36, 313 - 321
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
Ansari MA. et al, (2017), Nat Genet, 49, 666 - 673
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
Swadling L. et al, (2016), Vaccines (Basel), 4
Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Kelly C. et al, (2016), Hepatology, 63, 1455 - 1470
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
von Delft A. et al, (2016), Gut, 65, 112 - 123
THE GENERATION OF AN IMMUNOGENIC SECOND-GENERATION CONSERVED SEGMENT HCV T CELLVACCINE TO TARGET MULTIPLE HCV GENOTYPES
Von Delft A. et al, (2016), JOURNAL OF HEPATOLOGY, 64, S506 - S506
Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.
Clutton G. et al, (2013), Eur J Immunol, 43, 2875 - 2885
Quantitative trait loci mapping of the mouse plasma proteome (pQTL).
Holdt LM. et al, (2013), Genetics, 193, 601 - 608
HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
Humphreys IS. et al, (2012), Gut, 61, 1589 - 1599